Sagimet Biosciences (NASDAQ:SGMT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Head-To-Head Survey

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Sagimet Biosciences (NASDAQ:SGMT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiniksa Pharmaceuticals International and Sagimet Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0	1	8	0	2.89
Sagimet Biosciences	2	1	9	0	2.58

Kiniksa Pharmaceuticals International presently has a consensus target price of $93.14, indicating a potential upside of 18.52%. Sagimet Biosciences has a consensus target price of $26.63, indicating a potential upside of 232.10%. Given Sagimet Biosciences’ higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Kiniksa Pharmaceuticals International.

Risk & Volatility

Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.46, indicating that its stock price is 246% more volatile than the S&P 500.

Profitability

This table compares Kiniksa Pharmaceuticals International and Sagimet Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Valuation and Earnings

This table compares Kiniksa Pharmaceuticals International and Sagimet Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56 million	9.05	$59.01 million	$0.97	81.02
Sagimet Biosciences	$2.00 million	249.26	-$51.04 million	($1.28)	-6.27

Kiniksa Pharmaceuticals International has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

53.9% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Sagimet Biosciences on 9 of the 14 factors compared between the two stocks.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.